Gilead Sciences Inc. on Jan. 14 notified the U.S. health regulator of the company’s decision to voluntarily withdraw the use of the drug Zydelig for two types of cancer – follicular lymphoma and small lymphocytic leukemia.
Roche Holding AG decided to withdraw the company’s immunotherapy Tecentriq as a treatment for a type of breast cancer in the United States, the drugmaker said on Aug. 26 following a consultation with the Food and Drug Administration.
Bristol Myers Squibb is withdrawing the biopharmaceutical giant’s Istodax from the market after recent trials showed that the peripheral T-cell lymphoma drug did not achieve primary efficacy endpoint.
After a disappointing end to a nine-year trial, the U.S. Food and Drug Administration officially gave AMAG Pharmaceuticals notice of the proposal to withdraw approval of Makena, an injectable progestin treatment to reduce preterm births.
The U.S. Food and Drug Administration is requesting makers of all versions of the heartburn drug Zantac to remove the products from the market immediately due to the presence of a probable carcinogen.
The U.S. Food and Drug Administration called for Eisai to pull the company’s Belviq and Belviq XR for weight loss from the market after clinical trials demonstrated an increased incidence of cancer in users.